Despite the growing number of available agents designed to retard cancer growth, alkylating agents remain an important mainstay of cancer therapeutics. However, effective modulation of existing agents is necessary both to improve efficacy and to attenuate toxicity. Of the clinically useful alkylating agents, cyclophosphamide and ifosfamide are widely used for a variety of solid and hematologic malignancies and are thus important targets for manipulation. Major clinical toxicities include urotoxicity, nephrotoxicity, neurotoxicity, and, to a lesser extent, a risk of secondary leukemias. An important issue that has been raised, but not addressed directly, is the possibility that the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (MGMT), protects against toxicities associated with ifosfamide and cyclophosphamide.
Specific aims 1 and 2 will establish if MGMT plays a role in protecting against secondary leukemia by evaluating the repair of DNA adducts introduced by cyclophosphamide and ifosfamide by MGMT. Initially, we will determine if acrolein creates toxic/mutagenic lesions on DNA that are repaired by MGMT. These studies will be extended to the Nfl+/- mouse model of cyclophosphamide-induced leukemia. Shannon and colleagues have shown that mice heterozygous for the Nf1 gene, which encodes for a GTPase activating protein of Ras, have a higher incidence of leukemia at 15 months of age after treatment with cyclophosphamide than wild type mice. The NF1+/- mouse model of alkylating agent-induced leukemia will be crossed with MGMT-/- mice to determine if the absence of MGMT (Nfl+/-, MGMT-/-) results in an increase in the incidence of leukemia after treatment with cyclophosphamide as compared to littermates wild type for MGMT (Nf1+/-, MGMT+/+).
Specific aim 3 will focus on modulating the antitumor effect of cyclophosphamide and ifosfamide without increasing toxicities associated with acrolein or chloracetaldehyde (CAA). We have identified substituted guanine analogs that increase the sensitivity of human cancer cells to phosphoramide mustard (PM), isophosphoramide mustard (IPM) but not CAA or acrolein. We will determine if the mechanism of enhancement is due to inhibition of repair of crosslinks. In this renewal, we will continue to work towards our long-term goal of developing means to protect against the toxic and mutagenic effects of alkylating agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA081485-08
Application #
7215552
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Forry, Suzanne L
Project Start
1999-07-01
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
8
Fiscal Year
2007
Total Cost
$248,806
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Pinto, Navin; Ludeman, Susan M; Dolan, M Eileen (2009) Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10:1897-903
Horton, Terzah M; Jenkins, Gaye; Pati, Debananda et al. (2009) Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 8:2232-42
Rabik, Cara A; Maryon, Edward B; Kasza, Kristen et al. (2009) Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 64:133-42
Nagasubramanian, Ramamoorthy; Hansen, Ryan J; Delaney, Shannon M et al. (2008) Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure. Mutagenesis 23:341-6
Rabik, Cara A; Fishel, Melissa L; Holleran, Julianne L et al. (2008) Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther 327:442-52
Hansen, Ryan J; Ludeman, Susan M; Paikoff, Sari J et al. (2007) Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst) 6:1145-54
Rabik, Cara A; Dolan, M Eileen (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23
Hansen, Ryan J; Nagasubramanian, Ramamoorthy; Delaney, Shannon M et al. (2007) Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis 28:1111-6
Fishel, Melissa L; Rabik, Cara A; Bleibel, Wasim K et al. (2006) Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol 71:239-47
Rabik, Cara A; Njoku, Maria Chidiamara; Dolan, M Eileen (2006) Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32:261-76

Showing the most recent 10 out of 22 publications